Farnam Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273K Hold
773
– – 0.2% 52
2026
Q2
$227K Sell
773
-375
-33% -$106K 0.17% 51
2026
Q1
$320K Sell
1,148
-1,190
-51% -$343K 0.26% 42
2025
Q4
$708K Sell
2,338
-165
-7% -$51.5K 0.53% 34
2025
Q3
$702K Sell
2,503
-1,291
-34% -$351K 0.55% 33
2025
Q2
$916K Sell
3,794
-1,247
-25% -$295K 0.82% 30
2025
Q1
$1.23M Sell
5,041
-1,463
-22% -$440K 1.25% 21
2024
Q4
$2.14M Sell
6,504
-293
-4% -$99.5K 2.23% 12
2024
Q3
$2.27M Buy
+6,797
New +$2.16M 2.5% 9

Other funds holding BIO

Farnam Financial's BIO Position: Q3 2026 in Review

Farnam Financial held its Bio-Rad Laboratories Class A (BIO) position steady in Q3 2026 at 773 shares worth $273K. The position accounts for 0.2% of the portfolio, ranked #52.

Farnam Financial first reported a position in BIO in Q3 2024 and has held it in 9 quarters since. The position peaked at $2.27M in Q3 2024. 415 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • Farnam Financial held 773 shares of Bio-Rad Laboratories Class A worth $273K as of Q3 2026.
  • Farnam Financial left its Bio-Rad Laboratories Class A share count unchanged in Q3 2026.
  • Bio-Rad Laboratories Class A made up 0.2% of Farnam Financial's portfolio in Q3 2026, its #52 holding.
  • Farnam Financial first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and has held it in 9 quarters since.
  • Farnam Financial's Bio-Rad Laboratories Class A position peaked at $2.27M in Q3 2024.
  • 415 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Farnam Financial's 13F filing for Q3 2026, filed 21 Oct 2026.